HansaBioMed Life Sciences Ltd’s Post

Ischemic stroke is a major global health concern, causing nearly 10% mortality and 5% disability worldwide. As one of its major effects is blood-brain barrier (#BBB) disruption, the target of #therapeutic efforts to ameliorate neurologic functions is to restore BBB permeability. As #EVs are one of the hot topics for such efforts, Yiyang Li and colleagues investigated the therapeutic effects of bone marrow #mesenchymalstemcells (BMSC) EVs and brain endothelial cells (BEC) EVs comparatively. After isolating EVs by combination of HansaBioMed Life Sciences Ltd Exo-Prep and ultrafiltration, End3 cells were utilized to assess the therapeutic efficacy. Through these efforts, the researchers succeeded in demonstrating that Caveolin-1 deteriorates BBB permeability in acute ischemic stroke. More importantly, their results managed to demonstrate that EVs treatment can indeed restore neurological function, with BMSC-EVs being superior to BEC-EVs in this regard. https://lnkd.in/dsK7rR3W

Comparative study of extracellular vesicles derived from mesenchymal stem cells and brain endothelial cells attenuating blood-brain barrier permeability via regulating Caveolin-1-dependent ZO-1 and Claudin-5 endocytosis in acute ischemic stroke - PubMed

Comparative study of extracellular vesicles derived from mesenchymal stem cells and brain endothelial cells attenuating blood-brain barrier permeability via regulating Caveolin-1-dependent ZO-1 and Claudin-5 endocytosis in acute ischemic stroke - PubMed

pubmed.ncbi.nlm.nih.gov

To view or add a comment, sign in

Explore topics